ABSTRACT
Relevance Management of symptoms like anxiety, delirium and agitation cannot be neglected in COVID-19 patients. Antipsychotics are usually used for the pharmacological management of delirium, and confusion and behavioral disturbances. The selection of concomitant COVID-19 medications and antipsychotics should be evidence-based and closely monitored
Objective To systematically review evidence-based available on drug-drug interactions between COVID-19 treatments and antipsychotics.
Evidence Review Three databases were consulted: (a) Lexicomp® Drug Interactions, (b) Micromedex® Solutions Drugs Interactions, (c) Liverpool © Drug Interaction Group for COVID-19 therapies. To acquire more information on QT prolongation and TdP, the CredibleMeds® QTDrugs List was searched. Based on the information collected, the authors made a recommendation agreed to by consensus. In addition, a systematic review was conducted to find the clinical outcomes of drug-drug interactions between COVID-19 treatments and antipsychotics
Results The main interaction between COVID-19 drugs and antipsychotics are the risk of QT prolongation and TdP, and CYP interactions. Remdesivir, favipiravir, baricinitib, and anakinra can be used concomitantly with antipsychotics with no risk of drug-drug interaction (except for hematological risk with clozapine and baricinitib). Tocilizumab is rather safe to use in combination with antipsychotics, although it can restore the activity of CYP3A4 and therefore its substrate metabolism may increase. The most demanding COVID-19 treatments for co-administration with antipsychotics are chloroquine, hydroxychloroquine, azithromycin (all prolong QT interval) and lopinavir / ritonavir (CYP interaction and risk of QT prolongation).
Conclusions We urge to development of evidence-based guidelines that can help clinicians decide the safest treatment combination and monitoring necessary for each particular patient. The selection of concomitant COVID-19 medications and antipsychotics should be evidence-based and closely monitored.
INTRODUCTION
The number of people affected by coronavirus disease 2019 (COVID-19) worldwide is over 4.5M and rapidly increasing, and the importance of knowledge of symptom management and treatment for general practitioners and other clinicians must be stressed. Although the key symptoms are cough, fever, and breathlessness, anxiety, delirium, and agitation are also present in a large number of patients1. Up to 20–30% of COVID-19 patients will have with or develop delirium or changes in the mental health during their hospitalizations, and these numbers are as high as 60–70% in severely ill patients2,3. The duration of delirium has consistently proven an independent predictor of longer hospitalization, higher mortality, and higher cost4–6, and delirium is often inadequately managed7. Antipsychotics drugs (APs) are usually selected for the pharmacological management of delirium8, and confusion and behavioural disturbances associated with hospitalization of elderly patients9,10.
COVID-19 patients are being treated with Chloroquine, Hydroxychloroquine11,12, Azithromycin,13 and Lopinavir/ritonavir14, for the main symptoms, with risk of QT prolongation and TdP, and others drug-drug interactions (DDIs) in coadministration with antipsychotics. The very ill patients being treated, are the most likely to suffer from QT prolongation, because of the clinical condition known to prolong QT, and the concomitant drugs, and clinicians need to mitigate that risk15. This use is complicated by age-related decline in drug metabolism16, high incidence of concomitant physical illnesses, drug-drug interactions, and heightened sensitivity to APs17–19.
In addition, APs are associated with a proarrhythmic state and an increased risk of sudden cardiac death (SCD), with no substantial differences between first and second generation antipsychotics, and a dose-response effect20,21. Antipsychotics (exception Aripiprazole and Lurasidone) seem to be associated with a prolonged QT interval and an increased risk of SCD22. There are differences among APs in the degree of cardiotoxic effects23. SCD describes the unexpected natural death from a cardiac cause, within a short a time of a person who often has no prior cardiological condition that would appear fatal24. Many antipsychotics show a certain degree of blockade of potassium channels coded by the human ether-à-go-go related gene (hERG), thus inducing a QT interval prolongation and increasing the risk of polymorphic ventricular tachycardia/ torsade de Pointes (TdP)25,26. The most common acquired cause of long QT syndrome and TdP is drug induced QT interval prolongation. Intensive Care Unit patients are particularly prone to experience a QTc interval prolongation mainly due to certain drugs that can prolong the repolarization phase, either by their action mechanism or through the interaction with other drugs27. Elderly patients are in particularly prone to proarrhythmic risk with antipsychotics28. Also, the potential for pharmacokinetic DDIs of APs are mostly mediated by cytochrome P450 (CYP) enzymes metabolism, therefore physicians should be aware of coadministered drugs that may inhibit or induce these CYP enzymes29–31.
The aim of our review is to analyze the risks of DDIs and cardiovascular adverse events of antipsychotics with the main treatments currently used for COVID-19. More so, SARS-CoV-2 primarily affects the elderly with other associated cardiovascular risk factors, which often require hospitalization, and treatment of which is esencial to knowing the risk and safety of antipsychotics associated with COVID-19 treatments.
METHODS
Drugs currently used in the treatment of SARS-CoV-232, chloroquine, hydroxychloroquine, lopinavir/ritonavir, remdesivir, and tocilizumab have been reviewed. Also azithromycin with promising results13, and potential agents therapeutic agents such as favipiravir33, baricitinib34, and anakinra35.
Drug-drug interactions: antipsychotics and COVID19 drugs
Three databases were searched: (a) Lexicomp® Drug Interactions36, (b) Micromedex® Solutions Drugs Interactions37, and (c) Liverpool © Drug Interaction Group for COVID-19 therapies38. After an exhaustive review of various drugs interaction databases, the first two met the minimum quality criteria39, with good scores for scope, completeness, and ease of use40. The following information was extracted (when available): type of interaction, risk rating, and severity (both, according to the stratification in each database) and patient management recommendations.
QT prolongation and TdP risk
To find out more about QT prolongation and TdP, the CredibleMeds® QTDrugs List41 was searched. CredibleMeds® classifies drugs based on their risk of QT prolongation or TdP. Risk category: (a) Known Risk of TdP, (b) Possible Risk of TdP, (c) Conditional Risk of TdP.
Consensus recommendation
After the above information had been collected, the authors made consensus recommendations based on the following:
Not recommended (red zone), if (1) coadministration contraindicated in one or more databases, or (2) both drugs classified as “Known Risk of TdP” (risk of QT prolongation or TdP).
Recommended with caution. Two categories:
Potential interaction, which may require a dose adjustment, close monitoring, or choosing alternative agents, in two or more databases (orange zone).
b) Potential interaction intensity likely to be weak. Additional action/monitoring or dose adjustment unlikely to be required, in two or more databases (yellow zone).
Recommended (green zone), if little or no evidence of clinically significant interaction is expected in two or more databases.
When there were differences between databases, and it was not possible to reach an agreement by consensus, our recommendations reflect the most conservative approach.
When QT-prolongation is the main risk, we present the APs in two groups according to CredibleMeds® (“Possible” or “Conditional” risk) to increase the clinical information.
Systematic review
Additionally, a systematic review was conducted according to PRISMA guidelines42 (registration number in PROSPERO CRD42020183202) to find clinical outcomes of drug-drug interactions between COVID-19 treatment and antipsychotics.
We researched the following databases: MEDLINE, EMBASE, and Web of Science. The search was restricted to the English language using database filters. No dates restriction were imposed for the updated search. The search strategy will follow syntax: antipsychotic* AND (chloroquine OR hydroxychloroquine OR lopinavir OR ritonavir OR remdesivir OR tocilizumab OR azithromycin OR favipiravir OR baricitinib OR anakinra). The reference list of all identified articles identified were examined for any additional studies nor found in the first search.
Inclusion and exclusion criteria: The characteristics for a study to be eligible were (1) Publication reporting clinically significant drug-drug interactions (between antipsychotics and COVID-10 treatment in adult patients (whatever the disease prescribed for), (2) Type of publication: randomized controlled trial, other controlled study, observational study, case report and case series. Exclusion criteria: (1) Only pharmacokinetic studies (no clinical outcome), (2) Unpublished studies or gray literature and conference articles.
Three reviewers (G.R., A.R., M.R.) independently screened titles for the research question and criteria. When articles were deemed to meet the inclusion criteria by either reviewer, the abstract was analyzed. Full texts were retrieved when the reviewers were in agreement that the article met the inclusion criteria. Disagreements were solved by a fourth independent reviewer (B.P.). Rayyan QCR was used for duplicated data and screening43.
Data extraction: Two authors reached an agreement regarding the type of data to be collected, and relevant information such as the study design, context of drug interactions, clinical outcome, other comedication data and the numbers and types of patients was recorded.
Risk of bias and generalizability concerns in comparative studies were evaluated with an adaptation of the Newcastle-Ottawa quality assessment scale for case control and cohort studies44, an eight-item tool designed to rate methodological aspects of case-control and cohort studies, which includes three domains: study selection, comparability of cohorts on the basis of the design or analysis, and exposure. The overall score ranges from 0 to 9. Risk of bias and generalizability concerns in case reports and case series were evaluated with the Drug Interaction Probability Scale (DIPS) tool to assess the quality of papers retained45, This 10-question tool evaluates drug interaction causation. Scores < 2 indicate doubtful drug interaction, scores 2–4 possible, 5–8 probable and scores ≥ 9 indicate highly probable drug interaction.
RESULTS
The authors’ consensus recommendations are summarized in Table 1.
Drug-drug interaction between APs and Chloroquine/Hydroxychloroquine/Azithromycin
The primary interaction is the risk of QT prolongation and TdP because the three drugs for COVID-19, have “Known Risk of TdP” according to CredibleMeds®.
Recommended use of APs with these treatments is summarized in Table 2. Azithromycin is not included in the Liverpool© Drug Interaction Group, and therefore, some APs are marked as authors’ consensus agreement not possible. In that case, the recommendations reflect the most conservative approach, and they must be used with caution.
The summary information about the risk rating, severity and patient management for each database is available in Supplement Tables 1–3.
The recommended concomitant APs for use with these 3 COVID-19 drugs are: cariprazine, brexpiprazole and lurasidone. Asenapine may be used in combination with chloroquine and hydroxychloroquine, and olanzapine with hydroxychloroquine.
Drug-drug interaction between APs and Lopinavir/Ritonavir
This coadministration involves CYP interactions and the risk of QT prolongation and TdP. Lopinavir/ritonavir have “Possible Risk of TdP” according to CredibleMeds®. Lopinavir is metabolized primarily by hepatic CYP3A4 isoenzymes, and ritonavir is known to inhibit CYP3A4, CYP2D6, and to a lesser extent CYP2C9/10 and CYP2C19. Lopinavir/ritonavir is a strong inhibitor of CYP3A4, less of CYP2D6 and P-Glycoprotein (P-gp), and is a CYP1A2 (weak) and UGT1A4 inducer.
Table 3 summarizes the recommended uses of APs with lopinavir/ritonavir. There are no APs with little to no evidence of clinically significant interaction expected. We recommend olanzapine, with caution and monitoring patients for reduced clinical effect (ritonavir induction of CYP1A2), and risperidone, monitoring for increased AP effects and the risk of QT prolongation and/or TdP.
Information about risk ratings, severity and patient management in each database is summarized in Supplement Table 4.
Drug-drug interaction between APs and Remdesivir, and Favipiravir
Lexicomp® Drug Interactions and Liverpool© Drug Interaction Group report that there are no significant risks. Remdesivir and Favipiravir are not included in the Micromedex® Solutions Drugs Interactions database.
Drug-drug interaction between APs and Tocilizumab
Micromedex® Solutions Drug Interactions presents no drug-drug interaction, and although the Liverpool© Drug Interaction Group reports risk of hematological toxicity with clozapine, it does not present evidence of clinically significant risk with the rest of antipsychotics. However, according to Lexicomp® Drug Interactions, tocilizumab may decrease the serum concentration of CYP3A4 substrates like aripiprazole, brexpiprazole, cariprazine, haloperidol, lurasidone and quetiapine.
The information on risk rating, severity and patient management for each database is summarized in Supplement Table 5.
The authors’ consensus recommendation (see Table 1) is that brexpiprazole, cariprazine and lurasidone be used with caution. This is the most conservative approach, because they are not included in the Liverpool© database, and therefore, agreement is not possible.
Drug-drug interaction between APs and Baricinitib
Baricinitib is not included in the Liverpool© Drug Interaction Group and Micromedex® Solutions Drugs Interactions shows no drug-drug interaction with antipsychotics. The summary information about the risk rating, severity and patient management for each database is available in eTable 6 in the Supplement. All antipsychotics are recommended, but clozapine because of hematological risk (risk rating in zone yellow).
Drug-drug interaction between APs and Anakinra
Anakinra is not included in the Liverpool© Drug Interaction Group. Micromedex® Solutions Drugs Interactions and Lexicomp® Drug Interactions do not report any drug-drug interaction with antipsychotics.
Results of the systematic review
Of the 391 studies were screened and assessed for eligibility. After applying inclusion and exclusion criteria (Supplement eFigure 1), only 7 case reports were selected for inclusion. Data from all included studies are summarized in Table 4. Two case reports are considered highly probable drug interaction according to DIPS, one with lopinavir/ritonavir and quetiapine (with priapism as the clinical outcome), and with ritonavir/indinavir and risperidone (with acute dystonia and tremor exacerbation as the clinical outcome). There were no deaths among the 8 patients, but two fatal outcome, one patient in coma (Risperidone+Ritonavir) and 2 others with Neuroleptic Malignant Syndrome (Ritonavir+Aripiprazole, and Ritonavir+Risperidone), however all of them remitted.
There was no study or case report about QT prolongation and/or TdP between the drug of our study.
DISCUSSION
According to the DDIs databases and our systematic review, remdesivir, favipiravir, baricinitib, and anakinra may be concomitantly used with antipsychotics by clinicians for managing delirium, agitation or behavioral problems in COVID-19 patients with no risk of drug-drug interaction (except for hematological risk with clozapine and baricinitib reported only in one database).
Tocilizumab is quite safe for use in combination with antipsychotics, however, care should be taken with aripirazole, brexpiprazole, cariprazine, haloperidol, lurasidone and quetiapine, because of decreased exposure of APs, and with clozapine because of hematological risk). Tocilizumab binds to and inhibits the proinflammatory cytokine interleukin-6 (IL-6), and IL-6 decreased CYP3A4 mRNA by over 90%46.
Tocilizumab may restore CYP3A4 activity and thus increase CYP3A4 substrate metabolism. This effect may persist for several weeks following discontinuation of therapy due to the long half-life of tocilizumab. The COVID-19 treatments with the most risk for co-administration with antipsychotics are chloroquine, hydroxychloroquine, azithromycin, and lopinavir/ritonavir.
Most of the DDIs databases, point out the increased risk of prolonged QT interval with coadministration of chloroquine, hydroxychloroquine, and azithromycin with antipsychotics. Nevertheless, the cardiotoxicity of antimalarial drugs, with the exception of quinidine and halofantrine, which produce clinically significant prolongation of ventricular repolarization, remains to be confirmed47,48. In the present COVID scenario, Borba et al49 do not recommend the highest chloroquine dosage for patients critically ill with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir. Risk of prolonged QTc (over 500 milliseconds) was higher in patients receiving high doses (600 mg twice daily for 10 days) than a low-dosage group (450 mg twice on Day 1 followed by once daily for four days), 18.9% versus 11.1%, respectively. It is worth mentioning that all patients were also receiving azithromycin, and nearly all were receiving oseltamivir (both also prolong QT interval)50. Although treatment with hydroxychloroquine, azithromycin, or both, was not compared with either treatment, in 1438 hospitalized patients with COVID-19, it was not significantly associated with differences in in-hospital mortality51. In addition, grading antipsychotics by torsadogenic risk is not a simple issue, and attributable risk varies depending on the source.23,52
Our work also suggests that the coadministration of protease inhibitors, such as lopinavir/ritonavir, with APs should be cataloged as the most problematic combination, because of the CYP DDIs53 and the risk of QT prolongation and/or TdP. Although none APs seem to be recommended for used in combination with lopinavir/ritonavir, olanzapine might be considered as the safest option according to DDIs databases and also because none case report describing DDI has been reported. Ritonavir decreases systemic exposure to olanzapine through the induction of both CYP1A2 and UGT. Thus, patients on concomitant olanzapine and ritonavir may require higher doses (up to 50% more) of olanzapine to achieve similar plasma concentrations54,55
Strengths & Limitations
The use of drug interaction databases can be a useful clinical tool, but the lack of agreement between them limits their use56–60. Our study reviewed DDIs in 3 databases which fulfill quality criteria39,40, and a systematic review of the literature was also dome in search of possible clinical outcomes of these DDIs.
The main treatments used internationally for the treatment of COVID-19 were included, as well as most antipsychotics.
As limitations of our study, it should be noted that no studies were found beyond clinical cases which examined clinical results of the interaction between the drugs studied, so this information could not be presented.
CONCLUSIONS
In conclusion, the growing use of antipsychotics in COVID19 patients calls on the urges development evidence-based guidelines that can help clinicians decide on the safest treatment combination and the level of monitoring that would be warranted for each particular patient. The selection of concomitant COVID-19 medications and antipsychotics should be evidence-based and closely monitored. The main interactions between COVID-19 drugs and antipsychotics are the risk of QT prolongation and/or TdP, and CYP interactions.
Data Availability
Data is available in the article and supplementary material
Potential conflicts of Interest
Plasencia-García B.O., has received honoraria for consulting/advisory boards from Otsuka Pharmaceuticals, Lundbeck and Janssen Johnson & Johnson and lecture honoraria from Otsuka Pharmaceuticals, Lundbeck, Janssen Johnson & Johnson, Angelini and Pfizer. Crespo-Facorro B., has received honoraria for consulting/advisory boards from Otsuka Pharmaceuticals, Takeda, Angellini and lecture honoraria from Janssen Johnson & Johnson, Lundbeck, Roche and Otsuka Pharmaceutical. The other authors declare that they have no known conflicts of interest. No pharmaceutical industry or institutional sponsors participated in the study design, data collection, analysis, and interpretation of the results
ACKNOWLEDGEMENT SECTION
We would like to thank Carmen Jimenez, who encouraged us to start this work.
REFERENCES
